Our Story, Our Hope

DAUGHTERS AGAINST ALZHEIMER’S IS HONORED TO SUPPORT COLLABORATIVE WORK AMONG THE WORLD’S PREMIER DOCTORS, SCIENTISTS, AND RESEARCHERS AT EMORY’S GOIZUETA ALZHEIMER’S DISEASE RESEARCH CENTER.  Click here to learn more.

EARLY DIAGNOSTICS RELATING TO ALZHEIMER’S AND DEMENTIA - SPECIFICALLY BLOOD BASED BIOMARKER TESTS THAT WILL EASILY SCREEN AND HELP FACILITATE EFFECTIVE TREATMENT FOR ASYMPTOMATIC OR PRE-SYMPTOMATIC PEOPLE BEFORE COGNITIVE DECLINE BEGINS. 

“Daughters Against Alzheimer's (DAA) support has enabled the recent discovery of an exciting new set of proteins in blood that may provide insight into whether a person with amyloid-beta in the brain will develop cognitive symptoms during their lifetime. These proteins are found in the space outside of brain cells and interact with the amyloid-beta protein to potentially mediate the toxic effects of amyloid-beta plaques in the brain. Research support provided by DAA is now allowing researchers at Emory to investigate whether these novel proteins could be used to better assess the risk of future cognitive problems through a simple blood test taken during a routine primary care visit. Treatments for Alzheimer’s and dementia will be most effective if we can detect the different pathologies of the disease before cognitive problems occur. Blood-based biomarkers will change the way we diagnose and treat Alzheimer’s and dementia, allowing us to detect problems early and prevent future cognitive decline.”

-Erik Johnson, MD, PhD, Blood based biomarkers for Alzheimer’s Disease, Emory’s Goizueta Alzheimer’s Disease Research Center